ClinicalTrials.gg
Enrolling by invitationNCT06913985TrajectoryUpdated Nov 3, 2026

Trajectory Study: Predicting Cardiometabolic Health in Adolescents and Young Adults Based on Childhood Fitness, Sleep, and Diet

An observational study in Cardiometabolic Health, sponsored by Arkansas Children's Hospital Research Institute. Enrolling by invitation at 2 sites in United States. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Arkansas Children's Hospital Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
13 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Planned enrollment
13th of 49
250 · median 68
Started
2025
with 56 others
Observational
49 of 907
7 open now
Primary completion
2029-12
later than 174 of 185 live
Registered
803rd of 907
by date

Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 13th largest by planned enrollment of the 49 observational ones that give a count, is one of 57 that started in 2025, is one of 49 observational ones, reaches primary completion later than 174 of the 185 other live ones, and was the 803rd registered.

Sleep Initiation and Maintenance Disorders

2,734 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 13 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

The Trajectory study aims to determine whether childhood aerobic fitness, sleep quality, and diet quality predict cardiometabolic health during puberty and early adulthood, independently of adiposity.

Read the detailed description

The Trajectory study is a longitudinal observational study. Participants will be recalled from two existing pediatric cohorts: the Arkansas Active Kids study (ClinicalTrials.gov ID: NCT03221673; IRB #206217) and the MI Energy study (ClinicalTrials.gov ID: NCT04427462; IRB #260376). Both were cross-sectional studies with comparable designs, recruiting children between ages 7 and 10 years, regardless of sex, BMI, or ethnicity. The Trajectory study serves as the follow-up component during adolescence or early adulthood (ages 13-21). It is anticipated that approximately 250 participants will complete the follow-up visit.

During the follow-up visit at the Arkansas Children's Nutrition Center (ACNC), the following key measurements will be conducted:

  • Body Composition: Dual-Energy X-ray Absorptiometry (DXA)
  • Metabolic Profile: Fasting blood markers, including glucose, lipid profile, and insulin resistance
  • Continuous Glucose Monitoring: Interstitial sensor-based glucose
  • Vascular Function: Ultrasound (brachial artery flow-mediated dilation)
  • Liver Examination: Ultrasound (liver steatosis and stiffness)
  • Resting Metabolic Rate: Indirect calorimetry
  • Aerobic Capacity: Cardiopulmonary exercise test (spirometry)
  • Muscle Strength: Dynamometry
  • Physical Activity \& Sleep: Accelerometry
  • Dietary Intake: Food frequency questionary
03

Conditions studied

  • Cardiometabolic Health

Keywords

  • diet
  • physical fitness
  • adolescents
  • children
  • longitudinal study
  • diet quality
  • sleep quality
  • cardiovascular risk prediction
04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adolescents (13 to 17 years) and young adults (18 to 21 years) who previously participated in the Arkansas Active Kids study (clinicaltrials.gov #NCT03221673; IRB #206217) and the MI Energy study (clinicaltrials.gov #NCT04427462; IRB #260376).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 13 to 21 years.
  • Boys or girls.
  • All ethnicities.
  • All BMIs.
  • Previous participation in the Arkansas Active Kids study and the MI Energy study.
  • Participants who previously agreed to be contacted for future research at ACNC.
  • Participants who agree to the use of their previously collected information and samples from the AAK or MI Energy studies for the follow-up study.

Exclusion criteria

Exclusion Criteria:

  • Asthma that requires daily use of inhalers to keep symptoms under control.
  • Asthma that requires use of rescue inhalers (e.g., albuterol) >2 days per week.
  • Exercise-induced asthma.
  • Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).
  • Neurological disorders (e.g. epilepsy or seizures).
  • Cancer.
  • Hormonal disease (e.g., hypothyroidism and growth hormone deficiency).
  • diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis).
  • Bleeding disorders (e.g., hemophilia).
  • Chronic infections (e.g., , , ).
  • Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.
  • Pregnancy (verbal assessment).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Composite score of cardiometabolic health status.

    This composite outcome evaluates cardiometabolic health across two time points (pre-/early-adolescence and adolescence/early adulthood). It is calculated as the mean of z-scores for: fasting triglycerides and total cholesterol/HDL ratio (from fasting blood samples), HOMA2-IR (from fasting glucose and insulin), systolic blood pressure (automated sphygmomanometer), fat mass index \[DXA-derived fat mass (kg)/height²\], and inverse peak oxygen uptake (measured via graded exercise test with indirect calorimetry). The composite provides an overall measure of cardiometabolic health status. The goal is to assess whether childhood aerobic fitness, sleep quality, and diet quality independently predict this score, controlling for adiposity \[DXA-derived fat mass index (kg/m²)\].

    Time frame: Baseline assessment in childhood (ages 7-10) and follow-up assessment during adolescence or early adulthood (ages 13-21)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2029, 55 months after the start.

Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 55 months is above that.

Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 6, 2025
StartActual
May 20, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06913985
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
May 20, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Elisabet Borsheim, Ph.D
principal investigator · Arkansas Children's Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion